Azenosertib for the Treatment of Women with Recurrent or Persistent Uterine Serous Carcinoma

Inclusion Criteria

• Participants must have histologically or cytologically confirmed recurrent or persistent uterine serous carcinoma. For the purposes of this study, uterine carcinomas (with the exception of carcinosarcomas) that have any component that is considered serous will be considered a uterine serous carcinoma.
• Participants must have measurable disease, defined as at least one lesion that can be accurately measured per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
• Participants must have had one prior platinum-based chemotherapy regimen for management of advanced or metastatic uterine serous carcinoma. Participants with early-stage disease who received adjuvant platinum-based chemotherapy are also eligible if they recur within 12 months of their adjuvant therapy. Chemotherapy administered only in conjunction with primary radiation therapy (RT) as a radiosensitizer should not count as a systemic regimen. Patients who have had more than 3 prior lines of cytotoxic therapies may not have had prior episodes of febrile neutropenia. Additionally, participants must have a known tumor microsatellite instability (MSI) or mismatch repair (MMR) status and those participants with MSI-high or MMR-deficient tumors must have already received prior therapy with a PD-1 or PD-L1 immune checkpoint inhibitor or be deemed not to be a candidate for immune checkpoint therapy.
• Age 18 years or older. * Because no dosing or adverse event data are currently available on the use of azenosertib in participants < 18 years of age, children are excluded from this study.
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
• Absolute neutrophil count ≥ 1500/mcL
• Hemoglobin ≥ 9 g/dL (must be at least 2 weeks since any blood transfusion)
• Platelets ≥ 100,000/mcL
• Total bilirubin ≤ institutional upper limit of normal (ULN) or ≤ 1.5x ULN in patients with liver metastases or well-documented Gilbert's syndrome
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x institutional ULN or ≤ 5 x institutional ULN in patients with liver metastases
• Creatinine ≤ 1.5x institutional ULN or estimated creatinine clearance (CrCl) ≥ 60 mL/min
• Willingness to release archival tissue for research purposes.
• Biopsiable disease in a lesion that is not being utilized as the target lesion for RECIST assessment and willing to undergo pre- and on-treatment biopsies. Participants whose only biopsiable site is also the target lesion for RECIST assessment may still be eligible after discussion with the sponsor-investigator
• HIV-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. However, participants who are on antiretroviral therapy that includes strong inhibitors or inducers of CYP3A4 are not eligible, given the potential for interaction with azenosertib, which is a CYP3A4 substrate.
• Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Participants with new or progressive brain metastases (active brain metastases) are eligible only if the treating physician determines that immediate CNS-specific treatment is not required and is unlikely to be required during the first two cycles of therapy. Participants with known leptomeningeal disease are not eligible.
• Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
• The effects of azenosertib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Participants who have had chemotherapy, radiotherapy, or investigational therapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of azenosertib. Participants may not have had hormonal therapy within 2 weeks of the first dose of azenosertib.
• Participants who have not recovered from adverse events due to prior anti-cancer therapy administered more than 3 weeks before first dose of azenosertib (e.g., have residual toxicities > grade 1) with the exception of alopecia. Patients with stable grade 2 neuropathy that does not affect ability to perform activities of daily living (ADLs) or who have clinically recovered from prior adverse events but remain on appropriate medical management (e.g. therapeutic anticoagulation for thromboembolic events; anti-hypertensives for hypertension) may also be considered eligible for the study after discussion with the sponsor-investigator. Patients with residual grade 2 anemia who meet the marrow function criteria will also be considered eligible
• Participants who are receiving any other investigational agents for this condition.
• Participants may not have had prior receipt of a cell cycle checkpoint inhibitor (e.g., Chek1, Wee1, or ATR inhibition)
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to azenosertib.
• Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine.
• Pregnant women are excluded from this study because azenosertib is a deoxyribonucleic acid (DNA) damage repair pathway agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with azenosertib, breastfeeding should be discontinued if the mother is treated with azenosertib. * Women of childbearing potential (WoCBP) may be included only if acceptable contraception is in place for two weeks before study entry, for the duration of the treatment with the study drug and for 5 x half-lives of ZN-c3 + 6 months after the last dose of ZN-c3. Sexually active female subjects of childbearing potential must agree to use protocol-recommended method of contraception from the start of the screening period until 6 months after the last dose of study drug ZN-c3.
• Hospitalization for any reason within 14 days of starting study treatment
• Presence of indwelling urinary catheter
• Participants with evidence of an active or ongoing infection
• Participants must not have undergone major surgical procedures within 28 days of beginning study treatment or minor surgical procedures within 7 days of beginning study treatment. Port-a-cath placement will be allowed within a 7 day window of starting study treatment.
• Participants must be able to swallow oral medication and may not have refractory nausea and vomiting, have a percutaneous endoscopic gastrostomy (PEG) tube, be receiving total parenteral nutrition (TPN), or be dependent on intravenous (IV) fluid support.
• Because the composition, pharmacokinetic (PK), and metabolism of many herbal supplements are unknown, the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, cannabis, St. John’s wort, kava, ephedra (ma huang), ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, and ginseng). Participants should stop herbal medications at least 7 days prior to first dose of azenosertib.
• Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.